Irinotecan use during pregnancy.
BACKGROUND
Ovarian tumors during pregnancy are rare. There is sparse clinical evidence about the safety of chemotherapy in this situation.


METHODS
A 34-year-old woman was diagnosed by ultrasonography at 15 1/2 weeks of pregnancy with a Krukenberg tumor. She was treated with surgical removal and 10 courses of the combination of 5-fluorouracil, folinic acid, and irinotecan every 2 weeks until the 36th week of her pregnancy. The neonate was born without complications, and at age 4 months, showed normal development and no teratogenic effects.


CONCLUSIONS
In this case, irinotecan started at the second trimester and was safely used at full adjuvant dose.
Taylor
Justin
J
From the Division of Hematology Oncology, University of New Mexico Cancer Center, and Department of Gynecology and Obstetrics, University of New Mexico, Albuquerque, New Mexico.
Amanze
Adanna
A
Di Federico
Elaine
E
Verschraegen
Claire
C
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000473:pathology; D005260:Female; D006801:Humans; D000077146:Irinotecan; D007725:Krukenberg Tumor / Q000556:secondary / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000556:secondary / Q000628:therapy*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000473:pathology / Q000628:therapy*; D011295:Prenatal Care
D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin